CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex
Related Experiment Video
Updated: May 11, 2026

Correlating Gene-specific DNA Methylation Changes with Expression and Transcriptional Activity of Astrocytic KCNJ10 (Kir4.1)
Published on: September 26, 2015
Markênia Kélia Santos Alves1, Mário Henrique Girão Faria, Eduardo Henrique Cunha Neves Filho
1Universidade Federal do Ceará, Department of Pathology and Forensic Medicine, Rua Alexandre Baraúna, 949, Porangabussu, CEP 60183-630 Fortaleza, Brazil. markenialves@yahoo.com.br
Abstract:
CDKN2A promoter hypermethylation has been widely related to many cancers. In astrocytomas, although CDKN2A (p16(INK4A) protein) is often inactivated, there are still some controversial issues regarding the mechanism by which this alteration occurs. Thus, we analyzed a series of astrocytomas to assess the association between CDKN2A expression and methylation of grade I-IV tumors (WHO) and clinicopathological parameters. DNA extracted from formalin-fixed paraffin-embedded material of 93 astrocytic tumors was available for CDKN2A promoter methylation analysis and p16(INK4A) expression by methylation-specific PCR and immunohistochemistry, respectively. A strong negative correlation between nuclear and cytoplasmic immunostaining and CDKN2A promoter methylation was found. Additionally, a significant negative correlation between CDKN2A promoter methylation and age was observed; also, female patients had statistically more CDKN2A methylated promoters (p = 0.036) than men. In conclusion, CDKN2A inactivation by promoter methylation is a frequent event in astrocytomas and it is related to the age and sex of patients.
Insights
CDKN2A promoter methylation frequently inactivates the CDKN2A gene in astrocytomas. This epigenetic alteration correlates with patient age and sex, impacting p16(INK4A) protein expression.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- CDKN2A (p16(INK4A)) inactivation is common in astrocytomas.
- The precise mechanism of CDKN2A alteration in astrocytomas remains debated.
- Promoter hypermethylation is a known cancer-related epigenetic modification.
Purpose of the Study:
- To investigate the association between CDKN2A promoter methylation and p16(INK4A) expression in astrocytomas.
- To correlate CDKN2A methylation status with tumor grade and clinicopathological parameters.
- To elucidate the role of CDKN2A promoter methylation in astrocytoma pathogenesis.
Main Methods:
- Analysis of 93 astrocytic tumors (WHO grades I-IV) using formalin-fixed paraffin-embedded tissue.
- CDKN2A promoter methylation assessed via methylation-specific PCR.
- p16(INK4A) protein expression evaluated by immunohistochemistry.
Main Results:
- A strong negative correlation was observed between CDKN2A promoter methylation and p16(INK4A) expression (nuclear and cytoplasmic).
- CDKN2A promoter methylation showed a significant negative correlation with patient age.
- Female patients exhibited a higher frequency of CDKN2A methylated promoters compared to male patients (p=0.036).
Conclusions:
- CDKN2A inactivation via promoter methylation is a frequent event in astrocytomas.
- Patient age and sex are significant factors associated with CDKN2A promoter methylation in astrocytomas.
- Epigenetic silencing of CDKN2A contributes to astrocytoma development and progression.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
04:22Biomarker Identification for Gender Specificity of Alzheimer's Disease Based on the Glial Transcriptome Profiles
Published on: May 20, 2024
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation